Full Press Release Details
Sunshine Biopharma Reports 2025 First
Quarter Results, Revenues Up 18% Over Same Period Last Year
FORT LAUDERDALE, FL / ACCESSWIRE / May 15, 2025
/ Sunshine Biopharma Inc. (NASDAQ: "SBFM") (the "Company"), a pharmaceutical company offering and researching
life-saving medicines in a variety of therapeutic areas including oncology and antivirals today announced that it has filed its 2025 first
quarter report on Form 10-Q on Thursday, May 15, 2025. The following are highlights of the report:
"We are thrilled to report
strong financial results for the first quarter of 2025, with an 18% increase in revenues compared to the same period last year. This growth
reflects the continued dedication of our team, the trust of our customers, and the strength of our strategic initiatives. Sunshine Biopharma
remains steadfast in its commitment to innovation, operational excellence, and delivering value to our stakeholders. As we move forward,
we are focused on expanding our product pipeline, strengthening partnerships, and driving long-term sustainable growth. Our success is
a testament to the resilience and ingenuity of our organization, and I am confident that we will continue to build on this momentum throughout
the year," said Dr. Steve Slilaty, CEO of the Company.
The following are key elements of the
Income Statement contained in the Company's 2025 first quarter report:
| 2025Q1 | 2024Q1 | |||
| Revenue | $8,901,341 | $7,541,046 | ||
| Gross Profit | $2,730,426 | $2,354,337 | ||
| General & Administrative Expenses | $4,026,176 | $3,704,926 | ||
| Net Loss | $1,179,771 | $1,283,801 |
About Sunshine Biopharma Inc.
Sunshine Biopharma currently has 70 generic prescription
drugs on the market in Canada and 13 additional drugs scheduled to be launched in the remainder of 2025. Among the new drugs to be launched
is NIOPEG , a biosimilar of NEULASTA . Like NEULASTA , NIOPEG is a long-acting form of recombinant human granulocyte
colony-stimulating factor (filgrastim). It is indicated to decrease the incidence of infection in patients with non-myeloid malignancies
receiving anti-neoplastic therapy. In addition, Sunshine Biopharma is conducting a proprietary drug development program which is comprised
of (i) K1.1 mRNA, an mRNA-Lipid Nanoparticle targeted for liver cancer, and (ii) PLpro protease inhibitor, a small molecule for treatment
of SARS Coronavirus infections. For more information, please visit: www.sunshinebiopharma.com.
All registered trademarks are the property of
their respective owners.
Safe Harbor Forward-Looking Statements
This press release contains forward-looking
statements which are based on current expectations, forecasts, and assumptions of Sunshine Biopharma Inc. (the "Company")
that involve risks as well as uncertainties that could cause actual outcomes and results to differ materially from those anticipated or
expected. These statements appear in this release and include all statements that are not statements of historical fact regarding the
intent, belief or current expectations of the Company, including statements related to the Company's drug development activities,
financial performance, and future growth. These risks and uncertainties are further described in filings and reports by the Company with
the U.S. Securities and Exchange Commission (SEC). Actual results and the timing of certain events could differ materially from those
projected in or contemplated by the forward-looking statements due to a number of factors detailed from time to time in the Company's
filings with the SEC. Reference is hereby made to cautionary statements and risk factors set forth in the Company's most recent
For more information, please contact:
Camille Sebaaly, CFO